Scholar Rock: an Emerging Biotech Company for Spinal Muscular Atrophy With Potential in the Megamarket of Obesity
Reading Time: 3 minutes
Scholar Rock is a biopharmaceutical company focused on the discovery and development of drugs that specifically modulate the activation of growth factors in the context of disease. Apitegromab is being studied in the Phase 2 proof-of-concept trial EMBRAZE and is administered alongside GLP-1 medications for the treatment of patients with obesity. Data from this study is expected in the second quarter of 2025. The global market for obesity medications is projected to reach around $200 billion by 2031. Scholar Rock Holding (NASDAQ: SRRK)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
